Evolocumab
PCSK9 Inhibitors
Evolocumab shows particular CV benefit in those with autoimmune disease, inflammation
Patients with atherosclerosis and elevated LDL plus autoimmune or inflammatory disease may derive particular CV benefit from PCSK9 inhibition with evolocumab, a speaker reported.
Part of the Healio Network
PCSK9 Inhibitors Topic Review
Proprotein convertase subtilisin/kexin type 9 (PCSK9) is a protein that binds to the LDL receptor on hepatocytes, promoting its internalization and degradation within the cell. [Repatha package insert;9a]
Supreme Court decision allows alirocumab to stay on US market
The U.S. Supreme Court unanimously ruled in favor of Regeneron and Sanofi that two of Amgen’s patents for PCSK9 inhibitor technology were invalid, allowing alirocumab to stay on the U.S. market.
YELLOW III
Assessing the effect of evolocumab (Repatha, Amgen) on coronary plaque morphology using intravascular imaging and gene expression analysis in people with stable CAD on maximally tolerated statin therapy.
Imaging data may predict best responders to evolocumab therapy: YELLOW III
NEW ORLEANS — In adults with stable CAD on maximally tolerated statin therapy, more intensive lipid lowering with evolocumab was associated with favorable coronary plaque characteristics seen on multiple CV imaging modalities, data show.
FOURIER-OLE
Long-term safety of evolocumab (Repatha, Amgen) in FOURIER participants.
Long-term LDL cholesterol reduction with evolocumab reduces events, including CV death
Data from an open-label extension of the FOURIER study show use of the PCSK9 inhibitor evolocumab for more than 7 years led to durable reductions in LDL and a reduction in CV events, including CV death, according to a speaker.
Pre-PCI evolocumab did not prevent microvascular dysfunction when added to statin therapy
Pretreatment evolocumab did not lower risk for periprocedural microvascular dysfunction in patients undergoing elective PCI for stable CAD who were already on statin therapy for high LDL, researchers reported.
In high-risk adults, consider combination therapy up front to achieve LDL goals
High-risk patients with clinical atherosclerotic cardiovascular disease or multiple CV risk factors benefit from more intensive lipid-lowering therapy, and clinicians should initiate combination treatment sooner, according to a speaker.